GlassScriptPhysician profile
Stephen S Dayan
NPI 1134103500
$2,488.34
in general payments reported to CMS, 2019-2025
25 companies · $724 in 2025
The $724 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.37 · 2020: $113 · 2021: $270 · 2022: $321 · 2023: $385 · 2024: $584 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.42 |
| Education | $104.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.70 | 2021-2025 | Xifaxan |
| Abbvie INC. | $353.30 | 2019-2025 | Viberzi, Linzess, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $278.56 | 2021-2025 | Entyvio, Gammagard Liquid, Gattex |
| Janssen Biotech, INC. | $230.90 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Lundbeck LLC | $169.93 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $156.12 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $104.33 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $93.64 | 2019-2024 | Suflave, Sutab |
| Exact Sciences Corporation | $86.35 | 2024-2025 | Cologuard Collection Kit |
| Neurelis, INC. | $80.52 | 2023-2025 | Valtoco |
| Daiichi Sankyo INC. | $77.35 | 2019-2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $74.05 | 2025 | Amvuttra |
| Galderma Laboratories, L.P. | $56.12 | 2025 | |
| Merz North America, INC. | $43.06 | 2022 | |
| Corium, LLC | $37.57 | 2023-2024 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $35.54 | 2022 | |
| Dynavax Technologies Corporation | $29.97 | 2020-2021 | |
| Grifols USA, LLC | $25.84 | 2023 | Gamunex-C |
| Neurocrine Biosciences, INC. | $24.48 | 2023 | Ingrezza, Ongentys |
| Mirum Pharmaceuticals, INC. | $24.23 | 2025 | Livmarli, Cholbam, Chenodal |
| Redhill Biopharma INC. | $23.62 | 2023 | |
| Sandoz INC. | $23.08 | 2024 | Hyrimoz |
| Ardelyx, INC. | $22.45 | 2025 | Ibsrela |
| Orphalan INC | $21.76 | 2024 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $17.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.